COMMUNIQUÉS West-GlobeNewswire

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
03/02/2026
LIBERTY is part of the Company’s broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits to vulnerable Americans [...]
RadNet Enters Indiana with Acquisition of Northwest Radiology
03/02/2026
Purchase of six imaging centers establishes RadNet’s entry into the Midwestern United States LOS ANGELES, Feb. 03, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost- [...]
OrthoPediatrics Announces Expanded Enabling Technology Market Opportunity
03/02/2026
OrthoPediatrics partner iotaMotion receives FDA clearance for use of its iotaSOFT® cochlear implant insertion system in patients four years and older WARSAW, Ind., Feb. 03, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp [...]
NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2
03/02/2026
Exploratory Phase 2a study showed consistent and clinically meaningful functional improvements across muscle strength, motor performance, and patient-reported outcomes in patients with Charcot-Marie-Tooth disease (CMT) [...]
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
03/02/2026
Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the [...]
Zelluna promotes Emilie Gauthy to Chief Technology Officer
03/02/2026
Oslo, Norway, 03 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced the [...]
Persica Pharmaceuticals' Positive Clinical Data for PP353 Treatment of Chronic Low Back Pain Published in The Lancet's eClinicalMedicine
03/02/2026
First publication of clinical efficacy data for PP353, in development for chronic Low Back Pain Trial demonstrated that PP353 delivers clinically meaningful and durable reduction in pain and disability in patients with [...]
62,752 Orion Corporation A shares converted into B shares
03/02/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 3 FEBRUARY 2026 at 9.00 EET 62,752 Orion Corporation A shares converted into B shares In accordance with [...]
HemostOD awarded CHF 2 million Innosuisse grant to support key development milestones
03/02/2026
HemostOD awarded CHF 2 million Innosuisse grant to support key development milestones Lausanne, Switzerland — 03 February 2026 – HemostOD, a private Swiss company pioneering the ex vivo manufacturing of donor-free, off- [...]
PreciseOnco research consortium awarded EUR 14.9 million IHI grant to drive breakthroughs in precision cancer treatment
03/02/2026
February 3, 2026 Co-funded by the EU’s Innovative Health Initiative (IHI), the Philips-coordinated research consortium will combine advanced medical imaging, robotic guidance technologies, and AI to standardize and [...]
Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion
03/02/2026
Sanofi announces the signing of a share buyback mandate for up to €1 billion Paris, February 3, 2026. On January 29, 2026, Sanofi announced its intention to execute a share buyback program in 2026 of €1 billion. On [...]
NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2
03/02/2026
Exploratory Phase 2a study showed consistent and clinically meaningful functional improvements across muscle strength, motor performance, and patient-reported outcomes in patients with Charcot-Marie-Tooth disease (CMT) [...]
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®
03/02/2026
Lyon (France), Sao Paulo, (Brazil), February 3, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world’s largest biomedical research centers, today [...]
Communiqué de presse : Sanofi annonce la signature d’un mandat de rachat d'actions pour un montant maximum de 1 milliard d’euros
03/02/2026
Sanofi annonce la signature d’un mandat de rachat d'actions pour un montant maximum de 1 milliard d’euros Paris, 3 février 2026. Le 29 janvier 2026, Sanofi a annoncé son intention d’exécuter un programme de rachat d' [...]
Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day
03/02/2026
Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial disease Introduces napazimone ( [...]
Valneva et l'Instituto Butantan annoncent le début d'une stratégie pilote de vaccination au Brésil avec le vaccin à injection unique IXCHIQ® contre le chikunguny
03/02/2026
Valneva et l’Instituto Butantan annoncent l’initiation d’une campagne pilote de vaccination au Brésil avec le vaccin monodose contre le chikungunya IXCHIQ ® Lyon (France), Sao Paulo, (Brésil), le 3 février, 2026 – [...]
Natures Aid Introduces NSF-Certified Creatine Gummy Using Cold-Processing Technology
03/02/2026
HONG KONG, China, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Natures Aid has introduced an NSF-certified creatine gummy designed to provide a convenient alternative to traditional creatine formats such as powders and capsules, [...]
Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
03/02/2026
Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company [...]
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/02/2026
NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]

Pages